

cygenics



***A Healthcare Company
Focused On
Tissue & Cord Blood Banking***

Disclaimer

The material contained in this presentation must be considered as general background information on Cygenics Ltd. This presentation does not contain any earning guidance. The information presented is in summary form and where indicated figures used are unaudited. The information contained in this presentation is subject to risks and uncertainties that may cause actual results to differ materially from those indicated. This information should not be relied upon or seen as advice as to investors. Investors should obtain independent professional advice.

Corporate snapshot

KEY FINANCIALS

ASX Code:	CYN
Share Price:	\$0.30
Shares on Issue:	68.0m
Market Cap:	\$20.4m
Revenue: <i>(full year FY06)</i>	\$8.27m
Cash: <i>(Sept 2006)</i>	\$3.92m

MAJOR SHAREHOLDERS

Steven Fang <i>(Founder and CEO)</i>	12.8%
National Nominees <i>(Co-founders)</i>	8.2%
NEFCO Nominees <i>(IPO Investors)</i>	7.5%
Tar Choon Aw <i>(Co-founder)</i>	5.5%
CitiCorp Nominees <i>(Investors)</i>	5.3%
QIC <i>(IPO Investor)</i>	4.9%
Mandalay Capital <i>(Chairman)</i>	4.4%

Business strategy



Tissue & Cord Blood Banking




Technology Investment Portfolio

Healthcare company focused on tissue and cord blood banking

Recent announcements

- **Chinese blood bank collaboration**
 - First step towards business activities in China, including cord blood banking
- **India market expansion**
 - Establishing alliances with key hospitals and leading obstetricians
 - New cord blood processing and storage facility to be established in Q2 2007
- **Indonesian market expansion**
 - Leading Indonesian pharma company takes 49% stake in CordLife Indonesia
 - New cord blood processing and storage facility to be established in early 2007
- **Focus on cord blood banking**
 - Focus on revenue generating tissue and cord blood banking businesses



Focus on revenue generating tissue and cord blood banking businesses

Tissue and cord blood banking



- **Nature of business**
 - Collection, processing and storage of Cord Blood Stem Cells
 - Used in transplant (75 cancers & diseases)
 - Moving to therapy (heart, diabetes, stroke)

- **Revenue & Margins**
 - Upfront **\$1,300**, gross margin **50%**
 - Annuity **\$190**, locked in for **18 years**

What are Stem Cells ?

Simple business model

Market Dynamics



- **Existing market**
 - North Asia 23,000 cord blood units banked privately

- **Market growth drivers**
 - Clinical acceptance
 - Growing number of cord blood stem cell transplants
 - Consumer awareness

- **People want to use the service**
 - Improve future healthcare outcome & reduce costs
 - Therapy moving into common diseases (heart, diabetes, stroke)


Increasing demand for tissue and cord blood banking

Projected Market Growth

Financial Year	FY05	FY06	FY07	FY08
Market	Singapore SE Asia	Singapore SE Asia Australia	Singapore SE Asia Australia India Indonesia	Singapore SE Asia Australia India Indonesia China
Accessible Market <i>Internal estimate based on the number of births, adjusted for disposable income and market uptake data</i>	8,500	12,600	25,000	286,000
Client Numbers <i>Actual and Projected</i>	3,000	6,000	12,000	26,000
Cord Blood Banking Revenue	\$1.6m	\$3.6m		
Including Annuity of	\$95,000	\$300,000	\$750,000	

Strong projected regional growth

Company Revenue Growth



*IPO proforma

Significant revenue growth

Competitive Landscape



- Leadership position

	Cygenics	Competitors
Scale	Regional	Local
Brand	Regional & Local	Local
Operations	Regional & Local	Local
Quality Standards	International & Local	Local
Economies	Scale	Minimal

Minimal competition

Company value drivers



- **Increasing regional presence**
 - Existing markets: Australia, Singapore, Hong Kong, Indonesia, Thailand
 - Growth markets: India, China, Indonesia
- **Focus on organic growth**
- **Driving inorganic growth** through M&A and alliances
- **Co-development/out-licensing opportunities** with technology portfolio

Largest network of private cord blood banks in the region

Technology Investment Portfolio

Investee Company	Nature of Business	Current Holdings	Target Holdings
Cytomatrix	RegenImmune, T-cell production technology with ongoing grant projects PACRIMA (Europe), DCPrime (Malaysia) and BioDeakin ¹ (Australia)	100%	20%
	TranStem, Adult Stem Cell expansion technology with ongoing grant projects BioDeakin ¹ (Australia)	100%	20%
Cytovations	Bioreactor / Biologics technology with ongoing grant projects BioDeakin ¹ (Australia)	100%	20%
CLS	Medical referrals business	100%	20%
Pharmacell	Biologics cGMP manufacturing business	20%	20%
DNAPro	Product distribution and logistics business	19.7%	19.7%

Note 1 : Not yet awarded

A compelling investment opportunity



- High growth healthcare business
- The only regional cord blood banking company
- Scalable & proven business model
- Growing annuity revenue stream
- Technology investment portfolio upside

High growth healthcare business

Contact Details

Steven Fang, CEO
Mobile +61 (0)400 933 243
Email steven.fang@cygenics.com

Ian Brown, COO
Mobile +61 (0)438 565 212
Email ian.brown@cygenics.com

Cygenics Limited
Level 2, 405 Lt Bourke St
Melbourne, Victoria 3000, Australia
Telephone +61 (0)3 9642 5580
Facsimile +61 (0)3 9642 5581
Web www.cygenics.com